Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

113 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Transmitted drug resistant HIV-1 and association with virologic and CD4 cell count response to combination antiretroviral therapy in the EuroSIDA Study.
Bannister WP, Cozzi-Lepri A, Clotet B, Mocroft A, Kjaer J, Reiss P, von Wyl V, Lazzarin A, Katlama C, Phillips AN, Ruiz L, Lundgren JD; EuroSIDA study group. Bannister WP, et al. J Acquir Immune Defic Syndr. 2008 Jul 1;48(3):324-33. doi: 10.1097/QAI.0b013e31817ae5c0. J Acquir Immune Defic Syndr. 2008. PMID: 18545152 Clinical Trial.
Differential effects of efavirenz, lopinavir/r, and atazanavir/r on the initial viral decay rate in treatment naïve HIV-1-infected patients.
Edén A, Andersson LM, Andersson O, Flamholc L, Josephson F, Nilsson S, Ormaasen V, Svedhem V, Säll C, Sönnerborg A, Tunbäck P, Gisslén M. Edén A, et al. Among authors: ormaasen v. AIDS Res Hum Retroviruses. 2010 May;26(5):533-40. doi: 10.1089/aid.2009.0177. AIDS Res Hum Retroviruses. 2010. PMID: 20455766 Clinical Trial.
Non-linear mixed effects modeling of antiretroviral drug response after administration of lopinavir, atazanavir and efavirenz containing regimens to treatment-naïve HIV-1 infected patients.
Röshammar D, Simonsson US, Ekvall H, Flamholc L, Ormaasen V, Vesterbacka J, Wallmark E, Ashton M, Gisslén M. Röshammar D, et al. Among authors: ormaasen v. J Pharmacokinet Pharmacodyn. 2011 Dec;38(6):727-42. doi: 10.1007/s10928-011-9217-1. Epub 2011 Oct 2. J Pharmacokinet Pharmacodyn. 2011. PMID: 21964996 Clinical Trial.
Lopinavir/ritonavir, atazanavir/ritonavir, and efavirenz in antiretroviral-naïve HIV-1-infected individuals over 144 weeks: an open-label randomized controlled trial.
Andersson LM, Vesterbacka J, Blaxhult A, Flamholc L, Nilsson S, Ormaasen V, Sönnerborg A, Gisslén M. Andersson LM, et al. Among authors: ormaasen v. Scand J Infect Dis. 2013 Jul;45(7):543-51. doi: 10.3109/00365548.2012.756985. Epub 2013 Jan 7. Scand J Infect Dis. 2013. PMID: 23294034 Clinical Trial.
Stability of hepatitis C virus (HCV) RNA levels among interferon-naïve HIV/HCV-coinfected individuals treated with combination antiretroviral therapy.
Grint D, Peters L, Reekie J, Soriano V, Kirk O, Knysz B, Suetnov O, Lazzarin A, Ledergerber B, Rockstroh JK, Mocroft A; EuroSIDA in EuroCoord (European Coordinating Committee for the Integration of Ongoing Coordination Actions Related to Clinical and Epidemiological HIV Research). Grint D, et al. HIV Med. 2013 Jul;14(6):370-8. doi: 10.1111/hiv.12033. Epub 2013 Mar 27. HIV Med. 2013. PMID: 23534815 Free article.
113 results